Fund moves
77 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 6, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jul 2, 2026 · Filed Jul 7, 2026
A Regeneron Pharmaceuticals director sold $130K of Regeneron Pharmaceuticals shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$130,030
Shares × reported transaction price
64 days after results of Apr 29, 2026, 4 days before results of Jul 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $654.27 on Jul 2, 2026, 22% above its 52-week low and 19% below its high, after a 4% rise over the previous 30 trading days
52-week range $538.11 (Jul 7, 2025) to $812.27 (Jan 7, 2026), 42% of the way up, from 251 adjusted closes. 30 trading days earlier: $630.30 on May 19, 2026. Describes the past only, not a forecast
RSI 60, 7% under its 200-day average, at its 50-day average, 19% below the 52-week high, 20-day volatility 28% a year, against the S&P 500: +10 points over 1 month, −29 points over 3 months, −24 points over 6 months
From the adjusted closes up to Jul 2, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.2% | +1.3% | −1.0% |
| 30 days | +18.3% | +3.7% | +14.6% |
| 90 days | +11.4% | +4.5% | +6.9% |
Past results only. Not a forecast.
Fund moves
77 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 6, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
55 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 3, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
55 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 30, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.